The emerging data on genomic predictors in estrogen receptor–positive breast cancer suggest that the best treatment decisions are going to be made by integrating clinical, pathologic, and genomic measures.— Harold J. Burstein, MD, PhD
Genomic assays have had a powerful...!-->!-->
We are unlikely to manage this disorder with one or even several drugs in the way tyrosine kinase inhibitors have cured some people with CML. Different people are likely to need different therapies or combinations of therapies, which will need to be proved effective in controlled...!-->!-->
Stem cell transplant is associated with substantial morbidity and mortality, so our challenges are, first, to determine which patients are ideal candidates, and second, to know the opportune moment to proceed with stem cell transplant and the best means of doing so.!-->!-->—...
We have never seen such large benefits in progression-free survival in recurrent ovarian cancer. These landmark results could change the way we treat this disease.— Mansoor R. Mirza, MD
A landmark study showed that the investigational PARP (poly ADP-ribose polymerase)...!-->!-->
This study represents a significant step forward in the treatment of recurrent ovarian cancer. For exceptional responders, the natural history of the disease has changed.— Sandro Pignata, MD
“This study represents a significant step forward in the treatment of recurrent ...!-->!-->
Standard chemotherapy as neoadjuvant therapy is effective in these patients at high risk of relapse and is feasible in 90% of patients. These results may change the treatment of soft-tissue sarcoma of the extremities and trunk wall.— Alessandro Gronchi, MD
For the first ...!-->!-->
The evidence falls short, and further studies are needed with a longer follow-up, controlling for surgical expertise and including a control arm.— Axel Le Cesne, MD
“The debate about perioperative chemotherapy in localized high-grade soft-tissue sarcoma is never-ending. ...!-->!-->
We found that neoadjuvant administration of nivolumab is safe and feasible in stages I–IIIA NSCLC, and we also saw a preliminary signal that anti–PD-1 immunotherapy may have activity in early-stage disease.— Patrick Forde, MD
Neoadjuvant immunotherapy with the...!-->!-->
There is a huge effect on tumor cells when we give only two injections of a checkpoint inhibitor. We will be hearing a lot more about this.— Paul Baas, MD, PhD
Invited discussant Paul Baas, MD, PhD, of The Netherlands Cancer Institute, Amsterdam, first commented on the...!-->!-->
For patients with advanced non–small cell lung cancer (NSCLC) harboring the ALK gene rearrangement, ceritinib (Zykadia) provided longer progression-free survival than chemotherapy in patients previously treated with chemotherapy and crizotinib (Xalkori), but gastrointestinal toxicity was...
[ASCEND-5] will establish sequential crizotinib followed by a second-generation ALK inhibitor as the standard treatment for patients with metastatic ALK-positive lung cancer.— Alice T. Shaw, MD, PhD
Commenting on ASCEND-5, Alice T. Shaw, MD, PhD, Director of Thoracic...!-->!-->
The American Society of Hematology (ASH) recently announced the election of four new members to its Executive Committee for terms beginning after the 2016 ASH Annual Meeting, December 3–6, in San Diego.
Roy L. Silverstein, MD
Robert A. Brodsky, MD
John C. Byrd, MD
High-throughput sequencing of T-cell receptors may be a solution to some of the challenges confronting oncologists who treat cutaneous T-cell lymphomas. According to experts who presented talks on high-throughput sequencing of T-cell receptors at the 3rd World Congress of Cutaneous Lymphoma...
A collaboration of international experts is tackling the challenges involved in understanding and managing the treatment of cutaneous lymphomas. The Prospective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study from the Cutaneous Lymphoma International Consortium brings together...
Patients can respond in one lesion and not in another. It depends on where you sample.— Youn Kim, MD
Commenting on this talk during the discussion afterward, Youn Kim, MD, of Stanford University School of Medicine, Stanford, California, said: “At our center, we use...!-->!-->
John A. Martignetti, MD, PhD
Western Connecticut Health Network (WCHN) has named physician-scientist John A. Martignetti, MD, PhD, Network Director of the Laboratory for Translational Research at the WCHN Biomedical Research Institute. Dr. Martignetti is Associate Professor of Genetics and ...!-->!-->
Immunotherapy with an anti–programmed cell death protein 1 (PD-1) inhibitor—pembrolizumab (Keytruda)—showed encouraging responses in patients with advanced cutaneous T-cell lymphoma (either mycosis fungoides or Sézary syndrome). Pembrolizumab achieved a 38% overall response rate and responses...
Perry Robins, MD, and Deborah S. Sarnoff, MD
Perry Robins, MD, Founder and President of the Skin Cancer Foundation, was honored at the organization’s Champions for Change Gala, held October 18 at the Mandarin Oriental New York. Dr. Robins was honored at the event as a “Champion for Change” ...!-->!-->
Cutaneous T-cell lymphomas are a heterogeneous group of cancers. Some subtypes of cutaneous T-cell lymphomas are often misdiagnosed as benign skin diseases, making it challenging to gather reliable epidemiologic data.
At the 3rd World Congress of Cutaneous Lymphomas (sponsored by the International ...
I would encourage your patients with triple-negative breast cancer to seek out this [antiandrogen] approach in the context of clinical trials, so that we can understand the biology better and figure out how best to select patients.— Tiffany A. Traina, MD
A lot more data is expected from trials with CDK4/6 inhibitors, but part of the issue is going to be will we be using them all? Will they be used in sequence? Is there some unique way to use them with specific patients? All that remains to be defined.!-->!-->— William J....
The 2016 European Society for Medical Oncology (ESMO) Congress was jam-packed with studies of the anti–programmed cell death protein 1 (PD-1) antibodies in non–small cell lung cancer and melanoma, where they have clearly changed the treatment paradigm. Here is a roundup of some of those trials,...
In studies presented at the 2016 European Society for Surgical Oncology (ESMO) Congress, two different neoadjuvant treatment approaches improved the outcomes of patients with esophageal cancer.
Investigators from the Australasian Gastro-Intestinal Trials Group (AGITG) reported that the addition of ...
No survival or relapse data are yet shown [in the AGITG trial], and the question is whether histopathologic and clinical response will translate into a survival benefit.— Florian Lordick, MD
Florian Lordick, MD, Professor of Oncology and Director of the University...!-->!-->
Immunotherapy with anti–PD-1 (programmed cell death protein 1) and anti–PD-L1 (programmed cell death ligand 1) agents continues to advance in metastatic urothelial cancer, with positive showings in two clinical trials presented at the 2016 European Society for Medical Oncology (ESMO) Congress. The...
Anti–PD-1 and anti–PD-L1 agents represent a revolution in the treatment of advanced urothelial cancer. I believe that immunotherapy will be the treatment option for first- and second-line advanced urothelial cancer, but there are remaining questions.!-->!-->— Laurence Albiges,...
The 2016 European Society for Medical Oncology (ESMO) Congress revealed many important positive findings from key trials in a number of tumor types, but many highly anticipated phase III trials in advanced disease failed to meet their primary endpoints. The ASCO Post has summarized several of these ...
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs.
On October 24, 2016, pembrolizumab (Keytruda) was approved...
Among patients with locoregional clear-cell renal-cell carcinoma at high risk for tumor recurrence after nephrectomy, the median duration of disease-free survival was significantly longer in the sunitinib group than in the placebo group, at a cost of a higher rate of toxic ...!-->!-->
The time gained from adjuvant sunitinib therapy in disease-free survival is equivalent to time spent on treatment, implying a net zero gain. If a moderate trend toward benefit was observed, perhaps one could be more open-minded about this strategy....!-->!-->— Sumanta Kumar Pal, MD
Fred Hutchinson Cancer Research Center (Fred Hutch) has announced the official opening of a first-of-its-kind clinic dedicated to providing immunotherapies for cancer patients in clinical trials. The Bezos Family Immunotherapy Clinic, named in recognition of a family that has been deeply committed...
Dafna Bar-Sagi, PhD
Cancer researcher Dafna Bar-Sagi, PhD, has made fundamental contributions to the understanding of the mechanisms that drive the disease. In recognition of her accomplishments, she has been named a recipient of the Outstanding Investigator Award, an honor presented by...!-->!-->
Syed A. Abutalib, MD
Here is a brief look at the study findings and clinical implications of several recent and important clinical trials in neoplastic hematology. Attention is focused on myelodysplastic syndromes, multiple myeloma, and chronic lymphocytic leukemia.
In patients with advanced NSCLC and PD-L1 expression on at least 50% of tumor cells, pembrolizumab was associated with significantly longer progression-free and overall survival and with fewer adverse events than was platinum-based chemotherapy.!-->!-->— Martin Reck, MD, PhD, and ...
Deborah B. Doroshow, MD, PhD
Roy S. Herbst, MD, PhD
We are in the midst of a paradigm shift in lung cancer. In the past 2 years, the anti–programmed cell death protein 1 (anti–PD-1) inhibitors nivolumab (Opdivo) and pembrolizumab (Keytruda) were found to improve overall survival...!-->!-->!-->!-->
“The AMA House of Delegates, reflecting more than 170 state and specialty medical societies from across the country, today reaffirmed its commitment to health care reform that improves access to care for all patients.
“Using a comprehensive policy framework that has been refined over the past 2...
IMA901 did not improve overall survival when added to sunitinib as first-line treatment in patients with metastatic renal cell carcinoma.— Brian I. Rini, MD, and colleagues
In the phase III IMPRINT trial reported in The Lancet Oncology, Brian I. Rini, MD, of the...!-->!-->
If the ADAPT study replicates the results of the previous phase II study of AGS-003 plus sunitinib, this regimen will have the distinct advantage of being one of the most well-tolerated combinatorial regimens in the first-line setting for metastatic clear cell variant renal cell...!-->!-->
Richard Barakat, MD, FACS, Deputy Physician-in-Chief for the Regional Care Network and MSK Cancer Alliance, Memorial Sloan Kettering Cancer Center, New York
Steve Sugarman, MD, Chief of the Medical Oncology Service at Memorial Sloan Kettering Cancer Center, Commack, New York
The greatest challenge to individual scientists today is bringing together all the resources necessary to address the most challenging questions in immunotherapy. We are committed to reducing the barriers and helping researchers work together in a more efficient, seamless way.
The information contained in this Clinical Trials Resource Guide includes actively recruiting clinical studies focused on immunotherapy as treatment for non–small cell lung cancer (NSCLC). These studies are researching programmed cell death ligand 1 (PD-L1) antibody therapy; hypofractionated...
Earlier this month, ASCO announced it has collaborated with Innovative Oncology Business Solutions, Inc (IOBS) to launch ASCO COME HOME, a patient-centered oncology medical home, to help transition community oncology practices from volume-based care to value-based care and to prepare oncologists to ...
The Cholangiocarcinoma Foundation recently announced the opening of the Saha Laboratory for Liver Cancer Translational Research at the Fred Hutchinson Cancer Research Center in Seattle. Supriya Saha, MD, PhD, has joined scientists there to study the prevention, detection, and treatment of...
William D. Tap, MD
As reported by William D. Tap, MD, of Memorial Sloan Kettering Cancer Center, and colleagues in The Lancet, the addition of the anti-PDGFRα (platelet-derived growth factor receptor alpha) antibody olaratumab to doxorubicin resulted in prolonged progression-free and...!-->!-->
Margaret von Mehren, MD
The current plethora of drugs in development for oncology is leading to the testing of novel agents in common as well as rare diseases. Targeted therapies have been a focus of great interest in soft-tissue sarcomas, with testing of a variety of oral tyrosine kinase...!-->!-->
Kirsten K. Ness, PT, PhD
Although progress in treatment and supportive care for children with cancer has resulted in improved survival of these patients, some survivors experience ongoing medical conditions from their cancer or its treatment, including poor general health, poor mental...!-->!-->
The ASCO Post is pleased to present this special focus on the worldwide cancer burden. The aim of this special feature is to highlight the global cancer burden for various countries of the world.
For the convenience of the reader, each issue will focus on one country from one of the six regions...
More than 650 attendees gathered in San Francisco on September 9 and 10 for the 2016 Palliative Care in Oncology Symposium, focusing on the theme of “Patient-Centered Care Across the Cancer Continuum.” Research presented during the Symposium demonstrated how integrating palliative care into cancer...
ASCO is now accepting applications for its prestigious Health Policy Fellowship, a 1-year fellowship opportunity designed to give early-career oncologists the unique skills necessary to monitor and shape the regulatory and legislative policies that directly affect the practice environment and...
2016 Conquer Cancer Foundation Grants and Awards recipient receiving his award plaque during the 2016 Conquer Cancer Foundation Grants and Awards Ceremony. Left to right: ASCO CEO Clifford Hudis, MD, FACP, FASCO; Inaugural Jane C. Wright, MD, Endowed Young Investigator Award recipient Srinivas...
CancerLinQ LLC, a wholly owned nonprofit of ASCO, has announced that more than 1 million patient records are now in the CancerLinQ™ platform. In addition, 70 practices have signed agreements to participate in CancerLinQ™, representing more than 1,500 oncologists.
“We are excited to reach this...
Share the message of hope, strength, and a world free from the fear of cancer with greeting cards and eCertificates from the Conquer Cancer Foundation (CCF). In appreciation of your gift, CCF will mail or ship greeting cards, or e-mail eCertificates. Cards and eCertificates feature artwork...
Gina M. Villani, MD, MPH
In 2016 and 2017, a team from The Ralph Lauren Center for Cancer Care (RLCCC) is participating in an ASCO Quality Improvement Grant program, which is supported by the Stavros Niarchos Foundation. The grant program aims to improve the delivery of cancer care in...!-->!-->
Be sure to check out Cancer.Net’s updated ASCO Answers fact sheets on brain tumors; chronic lymphocytic leukemia; ovarian, fallopian tube, and peritoneal cancers; and oral and oropharyngeal cancers. These one-page (front and back) introductions include an overview of the disease,...
William H. Sharfman, MD
William H. Sharfman, MD, has been awarded the first Mary Jo Rogers Professorship in Cancer Immunology and Melanoma Research at Johns Hopkins University.
Dr. Sharfman is Associate Professor of Oncology and Dermatology, Director of Cutaneous Oncology, Clinical...!-->!-->
Charles G. Drake, MD, PhD
Charles G. Drake, MD, PhD, has joined NewYork-Presbyterian/Columbia University Medical Center as Director of Genitourinary Oncology and Associate Director for Clinical Research at the Herbert Irving Comprehensive Cancer Center. Dr. Drake will also serve as...!-->!-->
Biosimilars are among the newest threads in the fabric of cancer treatment in the United States, and they are spawning numerous questions for oncologists and patients with cancer. Many of these questions were taken up by participants in a recent Washington forum on “The Future of the U.S....
Jamie H. Von Roenn, MD
Addressing the evolving needs of cancer survivors at various stages of their illness and care, Palliative Care in Oncology is guest edited by Jamie H. Von Roenn, MD. Dr. Von Roenn is ASCO’s Senior Director of Education, Science and Professional...
As leaders within health-care institutions, physicians individually and collectively should:
Jennie R. Crews, MD, MMM, FACP, ACCC President (right), and Cary A. Presant, MD, FACP, FASCO, Recipient of the ACCC David King Award (left). Photo courtesy of the ACCC.
The Association of Community Cancer Centers (ACCC) honored Cary A. Presant, MD, FACP, FASCO, with the prestigious David...!-->!-->
The best approach to delivering value-based care is by subtraction, getting rid of waste. If a service or drug’s absolute benefit cannot be backed up by data, it should not be delivered.— Keith D. Eaton, MD, PhD
Over the past few years, the term value-based cancer care...!-->!-->
Anne Gross, PhD, RN, NEA-BC, FAAN
Anne Gross, PhD, RN, NEA-BC, FAAN, has been named Senior Vice President for Patient Care Services and Chief Nursing Officer at Dana-Farber Cancer Institute, effective December 1, 2016.
Dr. Gross joined Dana-Farber in 2002 after 12 years at Cambridge...!-->!-->
Susan J. Mandel, MD, MPH
Susan J. Mandel, MD, MPH, Director of Clinical Endocrinology and Diabetes for the University of Pennsylvania Health System, and Professor in the Division of Diabetes, Endocrinology, and Metabolism in Penn’s Perelman School of Medicine, has been elected...!-->!-->
The ASCO Post is pleased to reproduce installments of the “Art of Oncology” as published previously in the Journal of Clinical Oncology (JCO). For information on how you can submit your own essay for consideration in JCO’s Art of Oncology, visit
A randomized phase II clinical trial evaluating cabozantinib (Cabometyx) compared with standard-of-care sunitinib (Sutent) as first-line therapy for patients with advanced renal cell carcinoma has found that cabozantinib reduced the rate of disease progression or death by 34% compared with...
The use of nonpharmacologic interventions for symptom control can considerably empower cancer survivors in their pursuit to self-manage symptoms, improve self-care, and speed recovery.!-->!-->!-->!-->!-->!-->— Kathleen M. Wesa, MD (left), Lara Benusis, E-RYT 500 (center), and...
As our elected officials continue to debate about the financial risk corridors on the national stage, it would be wise to understand the downstream ramifications of their decisions on the real physical corridors in a hospital.— Chandrakanth Are, MBBS, MBA, FRCS, FACS
Dana-Farber Cancer Institute and Lifespan—Rhode Island’s first health system—leadership have signed a memorandum of understanding to form a partnership that will advance cancer treatment and expand research. The details will be finalized early next year.
“Over the past 6 months, our staff members...
Julie C. Brabbs, MBA
Julie C. Brabbs, MBA, was named Cancer Center Chief Administrative Officer at the University of Michigan (U-M) Comprehensive Cancer Center. She will also serve as Associate Director for Administration for the Center’s National Cancer Institute Cancer Center Support...!-->!-->
Shirley A. Johnson, RN, MS, MBA
Shirley A. Johnson, RN, MS, MBA, has been appointed as Roswell Park Cancer Institute’s Senior Vice President of Nursing and Patient Care Services and Chief Nursing Officer. Ms. Johnson officially joined the Roswell Park staff on October 31, 2016, bringing...!-->!-->
Carrie Lee, MD, MPH
Carrie Lee, MD, MPH, Medical Director of the University of North Carolina (UNC) Lineberger’s Clinical Protocol Office, has been appointed the Chair-Elect of the Association of American Cancer Institute’s (AACI) Clinical Research Initiative Steering Committee. Her Chair...!-->!-->
Lucy Kalanithi, MD, FACP
It should not come as a surprise to anyone who has read Dr. Paul Kalanithi’s brilliant—and unforgettable—memoir, When Breath Becomes Air (Random House, 2016), that nearly a year after publication, it remains on The New York Times best-seller list, its popularity...!-->!-->
Zhu Chen, MD, PhD
Hugues de Thé, MD, PhD
The American Society of Hematology (ASH) will honor Zhu Chen, MD, PhD, of Shanghai Institute of Hematology, and Hugues de Thé, MD, PhD, of Collège de France, with the 2016 Ernest Beutler Lecture and Prize for their significant research...!-->!-->!-->!-->
Michael O’Connell, MD
Michael O’Connell, MD, received the Association of Community Cancer Centers (ACCC) 2016 Clinical Research Award in recognition of the significant and positive impact of his research on the oncology patient, family, and the community. ACCC President Jennie R. Crews,...!-->!-->
58th ASH Annual Meeting & Exposition
December 3-6 • San Diego, California
For more information:
17th World Conference on Lung Cancer
December 4-7 • Vienna, Austria
For more information:
Memorial Sloan Kettering Cancer Center, Rockefeller University, and Weill Cornell Medicine have announced that they have established a new drug discovery company called Bridge Medicines. Launched in partnership with Takeda Pharmaceutical Company Ltd and health-care investment firms Bay City Capital ...
The following essay by Daniel G. Haller, MD, FASCO, FACP, FRCP, is adapted from The Big Casino: America’s Best Cancer Doctors Share Their Most Powerful Stories, which was coedited by Stan Winokur, MD, and Vincent Coppola and published in May 2014. The book is available on
Elisabeth Heath, MD, FACP
Elisabeth Heath, MD, FACP, Leader of the Genitourinary Oncology Multidisciplinary Team and the Patricia C. and E. Jan Hartmann Endowed Chair for Prostate Cancer Research at the Barbara Ann Karmanos Cancer Institute, was recently honored with the Michigan Cancer...!-->!-->
A “nascent movement to ‘go flat’” is how an article in The New York Times characterized the decisions by some women to opt out of reconstruction following surgery for breast cancer.1 The article examined the reasons several patients made that decision, which included avoiding multiple surgeries and ...
An article in The New York Times about women who had chosen not to have reconstruction following breast cancer surgery might prompt questions from newly diagnosed patients considering their options.1 Deanna J. Attai, MD, FACS, told The ASCO Post that whenever an article on breast cancer appears in...
The text and photograph on this page are excerpted from a four-volume series of books titled Oncology Tumors & Treatment: A Photographic History, by Stanley B. Burns, MD, FACS, and Elizabeth A. Burns. The photo below is from the volume titled “The X-Ray Era:...
Ly Vu, PhD
Ranjeet Kumar Sinha, PhD
The American Society of Hematology (ASH) recently announced that the following trainees received the highest-scoring abstracts in the categories of undergraduate student,...!-->!-->!-->!-->!-->!-->!-->!-->!-->!-->
J. Evan Sadler, MD, PhD
Ayalew Tefferi, MD
The American Society of Hematology (ASH) will recognize J. Evan Sadler, MD, PhD, of Washington University School of Medicine in St. Louis, and Ayalew Tefferi, MD, of Mayo Clinic College of Medicine, with the 2016 Henry M. Stratton Medal...!-->!-->!-->!-->
David Grimwade, PhD
The American Society of Hematology (ASH) will recognize the late David Grimwade, PhD, formerly of King’s College London and Guy’s and St. Thomas’ NHS Foundation Trust with the 2016 Exemplary Service Award for his exceptional years of service and dedication to the...!-->!-->
Launched in 2012 by Harborside Press, publisher of the Journal of the Advanced Practitioner in Oncology (JADPRO) and The ASCO Post, this year’s JADPRO Live at APSHO conference topped previous attendance records with nearly 1,100 attendees. APSHO, the Advanced Practitioner Society in Hematology and...
On November 10, 2016, the U.S. Food and Drug Administration (FDA) approved nivolumab (Opdivo) for the treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck with disease progression on or after a platinum-based therapy.
Approval was based on data from an...
Bing Zhang, PhD
Bing Zhang, PhD, a computational biologist with a focus on cancer bioinformatics, has been named the newest McNair Scholar at Baylor College of Medicine.
The McNair Scholar program at Baylor identifies influential researchers in breast and pancreatic cancers, juvenile...!-->!-->
Adrian Lee, PhD
Breast cancer researcher Adrian Lee, PhD, has been named Director of the Institute for Precision Medicine (IPM), a joint effort by the University of Pittsburgh Medical Center (UPMC) and the University of Pittsburgh to move biomedical research into personalized well-being...!-->!-->
Stand Up To Cancer (SU2C) is making $7.5 million in research grants available to early-career scientists who are pursuing innovative cancer research projects focusing on immuno-oncology, the American Association for Cancer Research recently announced. Funded by a grant from SU2C Visionary...
Most women with breast cancer reported high primary care physician quality, engagement, and communication, with a minority reporting high levels of primary care physician participation in treatment decisions, according to a study reported by Lauren P. Wallner, PhD, MPH, of the University of...
In an analysis reported in JAMA Oncology, Fumagalli et al identified genetic markers associated with pathologic complete response among women with early-stage HER2-positive breast cancer receiving neoadjuvant therapy in the phase III NeoALTTO trial. Christos Sotiriou, MD, PhD, of Institut Jules...
In the Prostate Cancer Prevention Trial finasteride was found to reduce the risk of low-grade prostate cancer but to have no effect on overall survival. Results of the trial, in which 18,880 men were randomized to receive finasteride or placebo for 7 years, were reported in 2003.
In a recent study ...
In the phase I/II CheckMate 032 trial reported in The Lancet Oncology, Padmanee Sharma, MD, of The University of Texas MD Anderson Cancer Center, and colleagues found that nivolumab (Opdivo) was active in locally advanced or metastatic urothelial carcinoma progressing after platinum-based therapy....
Having chronic cancer has been challenging, but I have no regrets. Just the opposite, I feel so lucky to have been diagnosed in 2007, 6 years after the U.S. Food and Drug Administration approved imatinib in the treatment of CML.— Jim Turner
Like many patients in the...!-->!-->